NBY - מכפיל P/S עתידי NovaBay

NovaBay Pharmaceuticals is recruiting leading ophthalmologists to develop innovative vision care products. Management has optimized the governance structure to reduce costs and increase reporting transparency. However, a cash deficit and shrinking margins are forcing the company to deplete its reserves. The forward price-to-sales valuation trend reflects a current market overvaluation, with the metric settling at 18.50.
NBY (NovaBay): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The forward P/S ratio assesses the market value of NovaBay Pharmaceuticals (NBY) relative to projected revenue, determining the extent of the premium paid for future cash flows. By analyzing the expected price-to-sales ratio at 18.50, an investor can evaluate the capitalization's resilience to the expansion of the Avenova brand across pharmacy chains and the efficiency of developing the high-margin direct-to-consumer (DTC) online sales segment.